483
RMA Long Island IVFRMA Long Island IVF – FDA 483, Mar 1, 2022
Record Details
An FDA inspection of RMA Long Island IVF in Melville, NY, revealed deficiencies in determining HCT/P donor eligibility. The firm failed to adequately screen oocyte donors for Zika virus risk factors and accepted donations from a donor with an incomplete risk factor questionnaire. These issues indicate a failure to ensure donor suitability prior to donation.
View Company Profile
ID · 28eb2e2c-2d3c-4993-bb38-0b030aecf5e6
Other documents for RMA Long Island IVF
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.